Irhythm Technologies Inc (NASDAQ:IRTC) EVP Sells $637,207.20 in Stock

Irhythm Technologies Inc (NASDAQ:IRTC) EVP David A. Vort sold 5,264 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $121.05, for a total transaction of $637,207.20. Following the sale, the executive vice president now directly owns 21,132 shares of the company’s stock, valued at approximately $2,558,028.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

David A. Vort also recently made the following trade(s):

  • On Monday, June 8th, David A. Vort sold 11,264 shares of Irhythm Technologies stock. The stock was sold at an average price of $119.57, for a total transaction of $1,346,836.48.

IRTC opened at $124.48 on Friday. The firm has a market capitalization of $3.36 billion, a PE ratio of -56.84 and a beta of 1.41. Irhythm Technologies Inc has a twelve month low of $56.24 and a twelve month high of $136.55. The firm’s 50-day moving average price is $117.17 and its 200 day moving average price is $101.05. The company has a current ratio of 3.60, a quick ratio of 3.51 and a debt-to-equity ratio of 0.92.

Irhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.23. The firm had revenue of $63.50 million for the quarter, compared to analyst estimates of $61.40 million. Irhythm Technologies had a negative net margin of 24.34% and a negative return on equity of 49.99%. Irhythm Technologies’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.33) earnings per share. As a group, analysts predict that Irhythm Technologies Inc will post -2.24 earnings per share for the current fiscal year.

A number of research firms have recently commented on IRTC. BTIG Research reissued a “buy” rating and set a $130.00 target price on shares of Irhythm Technologies in a research note on Friday, May 8th. Morgan Stanley boosted their target price on shares of Irhythm Technologies from $114.00 to $142.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Oppenheimer reissued a “hold” rating on shares of Irhythm Technologies in a research note on Friday, May 8th. JPMorgan Chase & Co. boosted their target price on shares of Irhythm Technologies from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, SunTrust Banks boosted their price target on shares of Irhythm Technologies from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $132.43.

Large investors have recently bought and sold shares of the business. Invesco Ltd. boosted its holdings in Irhythm Technologies by 141.5% in the 1st quarter. Invesco Ltd. now owns 862,234 shares of the company’s stock valued at $70,142,000 after purchasing an additional 505,219 shares during the last quarter. AlphaCrest Capital Management LLC boosted its holdings in Irhythm Technologies by 104.7% in the 1st quarter. AlphaCrest Capital Management LLC now owns 8,800 shares of the company’s stock valued at $716,000 after purchasing an additional 4,500 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Irhythm Technologies by 15.9% in the 1st quarter. Principal Financial Group Inc. now owns 22,886 shares of the company’s stock valued at $1,862,000 after purchasing an additional 3,133 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Irhythm Technologies by 7.9% in the 1st quarter. Geode Capital Management LLC now owns 387,963 shares of the company’s stock valued at $31,560,000 after purchasing an additional 28,269 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in Irhythm Technologies by 38.9% in the 1st quarter. Morgan Stanley now owns 292,338 shares of the company’s stock valued at $23,781,000 after purchasing an additional 81,895 shares during the last quarter.

About Irhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Recommended Story: How accurate is the Rule of 72?

Insider Buying and Selling by Quarter for Irhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.